These disorders, which include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are driven by acquired somatic mutations in genes such as JAK2, CALR, or MPL, leading to hyperactivation of the JAK/STAT signaling pathway [3, 4]. This evidence concerns the gene MPL and essential thrombocythemia.